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Adipocytes from streptozotocin-diabetic rats are -50-times more sensitive to the lipolytic action of 
glucagon. This change is only perceived in the presence of a small quantity of adenosine deaminase which 
itself has little effect on basal lipolysis. Insulin treatment restores glucagon sensitivity to normal. 
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1. INTRODUCTION 
Adipocytes from 24 h-fasted rats are more sen- 
sitive (by a factor of -10) to the lipolytic action of 
glucagon compared with cells from fed animals 
[l]. Adenylate cyclase in adipocyte plasma mem- 
branes is > lOO-times more sensitive to stimulation 
by glucagon after fasting [2]. It is not yet establish- 
ed whether these changes are due to altered 
glucagon-receptor interaction or result from 
changes in coupling between adenylate cyclase and 
the adipocyte glucagon receptor. 
In streptozotocin-diabetes, both adipocyte 
lipolysis and adenylate cyclase in fat-cell ghosts 
show a 3-fold increase in sensitivity to adrenaline 
[3]. The sensitivity of adenylate cyclase to cor- 
ticotropin was increased lo-fold in adipocyte 
ghosts from streptozotocin-diabetic rats [3]. 
Streptozotocin- or alloxan-induced iabetes in rats 
[4,5] and insulin-dependent diabetes in humans 
[6-81 is generally associated with hypergluca- 
gonaemia. By analogy with the ‘down regulation’ 
of insulin receptors frequently observed with 
elevated insulin levels [4,9,10], one might expect 
tissue responsiveness to glucagon to be diminished 
in diabetes. However, in two human conditions 
exhibiting hyperglucagonaemia (untreated insulin- 
dependent diabetes and in the case of uremic 
patients) the subjects are more sensitive to the 
Glucagon Lipoiysis Streptozotocin 
hyperglycaemic action of infused glucagon [ 11,121. 
Although in the diabetic patients this could simply 
reflect the loss of the restraining action of insulin, 
this cannot be so in the uremic patients since 
plasma insulin was normal, or even elevated [12]. 
In the streptozotocin-diabetic rat or the partially 
nephrectomized rat (a uremic animal model) the 
resultant hyperglucagonaemia s accompanied by 
increased rather than decreased binding of lz51- 
labelled glucagon to liver plasma membranes and 
by an increased stimulation of hepatic adenylate 
cyclase by glucagon [4,13]. 
Here, we have investigated the effect of strep- 
tozotocin diabetes upon the lipolytic response of 
rat adipocytes to glucagon and find it to be 
substantially increased. Insulin treatment of 
diabetic animals reversed this change. 
2. MATERIALS AND METHODS 
Male Sprague-Dawley rats bred in the animal 
colony at University College London were used 
throughout. Starting body weights are shown in 
table 1. Rats were made diabetic by subcutaneous 
injection on day 1 of streptozotocin (100 mg/kg) 
dissolved in 0.2 ml 50 mM citrate buffer (pH 4.0) 
containing 0.15 M NaCl. Control animals were 
similarly injected with saline-citrate alone. Con- 
trol animals were adjudged as being suitable for 
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Table 1 
Body weights and plasma glucose concentrations of experimental animals 
Treatment of animals Day 1 Day 3 
Control (30) Body wt (g) 159 + 1 170 * 1 _ 
Plasma glucose (mM) 11.8 k 1.2 - 
Diabetic (3 1) Body wt (g) 160 + 1 151 + 2 - 
Plasma glucose (mM) 33.0 + 1.4 - 
Diabetic, insulin-treated 
(on day 3) (25) 
Body wt (g) 164 k 1 151 ?I 2 177 +1 
Plasma glucose (mM) - - 8.0 + 0.9 
Animals were treated as described in the text. The values are means k SEM. The number of animals in each group is 
shown in parentheses 
the experiment if their growth over the following 
two days was normal (-5 g/day). On day 3, 
animals were selected as diabetic if showing a 
strongly positive ‘Clinistix’ test for urinary glucose 
(>OS% glucose, w/v). These animals lost weight 
and showed marked hyperglycaemia (table 1). 
Diabetic rats received bovine insulin subcutaneous- 
ly on days 3 and 4 at - 1O:OO h (20 units/kg of pro- 
tamine zinc beef insulin from Weddel Phar- 
maceuticals, London). Insulin-treated diabetic 
animals regained weight and showed normal 
glycaemia (table 1). Blood was collected into 
heparinized vessels immediately after decapitation 
and centrifuged to obtain plasma for enzymatic 
measurement of glucose [ 141. 
Chemicals were obtained as in [l]. Adenosine 
deaminase was dialysed to remove ammonium 
sulphate and standardized spectrophotometrically 
on the morning of the experiment, as in [l]. One 
milliunit of adenosine deaminase deaminates 
1 nmol adenosinelmin at 25°C. 
Adipocytes were isolated after disaggregation of 
epididymal adipose tissues with collagenase [151 
and were then incubated in 4 ml lots of Krebs- 
Henseleit saline medium 1161 containing defatted 
albumin (40 mg/ml) and 5 mM glucose as in [I]. 
Generally cells equivalent o l/5 of those obtained 
from one rat were added to each flask. After in- 
cubation, the flask contents were deproteinized 
with HC104 and glycerol measured [17]. Adipocyte 
DNA was measured as in [ 181. 
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3. RESULTS AND DISCUSSION 
Glucagon is not generally assigned a significant 
lipolytic role in mammalian adipose tissue [19]. In 
part, this is because, under the conditions generally 
used in vitro, high, unphysiological concentrations 
of the hormone are necessary to elicit a response 
which, even at its fullest, is considerably smaller 
than that seen with maximally effective concentra- 
tions of other lipolytic agents. Incubated 
adipocytes release small quantities of adenosine 
which, through interaction with ‘Ri’-type 
adenosine receptors [20] inhibits adenylate cyclase 
and attenuates the effects of lipolytic hormones 
[21-241. The lipolytic effect of glucagon is par- 
ticularly susceptible to the attenuating effect of 
adenosine. Removal of adenosine from cell in- 
cubations with adenosine deaminase increases the 
lipolytic efficacy of glucagon to a level comparable 
with that of noradrenaline or corticotropin [ 1,251 
and also reveals the substantial increase in sen- 
sitivity to glucagon seen in the fasted state [l]. 
Fig.la shows that addition of glucagon alone at 
up to 30 nM only elicited a weak lipolytic response 
under the 3 experimental conditions. Fig. lb shows 
that inclusion of a small amount of adenosine 
deaminase (8 munits/ml) in the incubations of 
cells had only a slight effect on basal lipolysis. In- 
clusion of adenosine deaminase, however, 
facilitated the lipolytic action of higher concentra- 
tions of glucagon in cells from control animals or 
from insulin-treated diabetic rats (fig. lb). This 
facilitation of glucagon-stimulated lipolysis was 
substantially greater with the cells from diabetic 
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Fig. 1. Dose-response curves of glucagon-stimulated 
lipolysis. Adipocytes were incubated for 1 h without (a) 
or with (b) adenosine deaminase (8 m units/ml). The 
values are means f SEM. In the presence of adenosine 
deaminase diabetes resulted in significantly increased 
lipolysis compared with the controls at the following 
[glucagon]: 3 x lo-” M and 8 x lo-” M, p c 0.05; 
1.5 x lo-’ M and 3 x lo-’ M, p < 0.01. Similar values 
for comparison of diabetics versus insulin-treated 
diabetics are: 3 x lo-” M and 3 x lo-’ M, p < 0.05; 
8 x lo-” M and 3 x lo-’ M, p < 0.02; 1.5 x lo-’ M, 
p < 0.01. (0) Controls (n = 5) (0) diabetics (n = 6); (H) 
insulin-treated diabetics (n = 4). The mean adipocyte 
DNA/ml flask contents was: controls, 6.6 pg; diabetics, 15 30 L5 60 75 90 
5.4 gg; insulin-treated diabetics, 7.9 pg. TIME (MIN.1 
animals. About 4 x 10-i’ M glucagon caused half- 
maximal stimulation of lipolysis in the diabetic 
state. Although a comparable value cannot be 
calculated directly from this experiment for the 
normal state, the maximum rate of glucagon- 
stimulated lipolysis observed in control cells with 
adenosine deaminase present is 
-25-30pmol.h-‘. 1OOpg DNA-’ [1,25]; i.e., 
comparable to or even greater than in the diabetic 
state. On this basis -2 x lo-’ M glucagon would 
be necessary to elicit half-maximal response in the 
normal state; i.e., the enhancement in sensitivity to 
glucagon in the diabetic state is -50-fold. Plasma 
glucagon levels in the rat have been reported over 
80-2000 pg/ml; i.e., -2 x lo-“-5 x lo-” M 
[5,26,27], the top end of this range encompassing 
various pathological states, including diabetic 
ketoacidosis. It is concluded therefore, that 
physiological concentrations of the hormone may 
be capable of eliciting an appreciable lipolytic 
response in the diabetic condition, but not in the 
normal state. The responsiveness hown here is ob- 
viously a minimal estimate since the biological 
potency of the commercial glucagon preparation 
used here is unknown. It is not known at present 
whether this apparent adaptation of the glucagon 
responsiveness of tissue is due to altered interac- 
tion of glucagon with its receptor or is a post- 
receptor event. In the diabetic animal it will be ac- 
companied by a fall in insulin and a rise in 
glucagon concentrations. 
Fig.lb also shows that insulin-treatment of 
diabetic animals abolished the hypersensitivity to 
the hormone. It is not known if this may be at- 
tributed to a direct action of insulin on the tissue 
Fig.2. Time courses of glucagon-stimulated lipolysis. 
Adipocytes were incubated with glucagon (3 x lo-’ M) 
and adenosine deaminase (8 munits/ml). Time courses 
in the absence of glucagon were linear (not shown). The 
values are means f SEM. (0) Controls (n = 4); (0) 
Diabetics (n = 7). The mean adipocyte DNA/ml flask 
contents was: controls, 4.6 pug; diabetics, 7.0 pg. 
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or could be secondary to the reduction in 
hyperglucagonaemia observed after administration 
of insulin to streptozotocin-diabetic rats [4]. 
Lipolytic hypersensitivity to adrenaline in diabetes 
is also reversible by insulin treatment [28]. 
Degradation of glucagon by incubated 
adipocytes may be considerable [29,30]. It was 
therefore considered possible that the difference in 
sensitivity might only be apparent and could be at- 
tributable to more rapid glucagon degradation in 
the normal state. If this were so, one would not ex- 
pect sustained, linear, time courses of glucagon- 
stimulated lipolysis in response to non-saturating 
concentrations of the hormone in the normal state. 
However, this was observed with the intermediate 
glucagon dose of 3 x 10e9 M (fig.2). Furthermore, 
and surprisingly, the time course with diabetic cells 
actually accelerated such that the lipolytic rate over 
the 60-90 min interval was g-times that seen in 
control cells. This is another unexplained facet of 
the action of glucagon in this tissue that requires 
consideration in further studies. 
REFERENCES 
111 
PI 
[31 
141 
151 
161 
171 
PI 
Honnor , R.C. and Saggerson, E.D. (1980) 
Biochem. J. 188, 757-761. 
Chohan, P. and Saggerson, E.D. (1982) FEBS Lett. 
146, 357-360. 
Zumstein, P., Zapf, J., Waldvogel, M. and 
Froesch, E.R. (1980) Eur. J. Biochem. 105, 
187-194. 
Soman, V. and Felig, P. (1978) J. Clin. Invest. 61, 
552-560. 
Meier, J.M., McGarry, J.D., Faloona, G.R., 
Unger, R.H. and Foster, D.W. (1972) J. Lipid Res. 
13, 228-233. 
Unger, R.H. and Orci, L. (1975) Lancet i, 14-16. 
Unger, R.H. (1976) Diabetes 25, 136-151. 
Barnes, A.J., Bloom, S.R., Mashiter, K., Alford, 
F.P., Smythe, P. and Turnell, D. (1976) 
Diabetologia 12, 379. 
PI 
1101 
1111 
WI 
131 
141 
151 
161 
1171 
1181 
1191 
WI 
WI 
WI 
1231 
1241 
1251 
LW 
v71 
WI 
WI 
1301 
Kahn, C.R., Neville, D.M. and Roth, J. (1973) J. 
Biol. Chem. 248, 244-250. 
Gavin, J.R., Roth, J., Neville, D.M., De Meyts, P. 
and Buell, D.N. (1974) Proc. Natl. Acad. Sci. USA 
71, 84-88. 
Shewin, R.S., Fisher, M., Hendler, R. and Felig, P. 
(1976) N. Eng. J. Med. 294, 455-461. 
Sherwin, R.S., Bastl, C., Findelstein, F.O., Fisher, 
M., Black, H., Hendler, R. and Felig, P. (1976) J. 
Clin. Invest. 57, 722-731. 
Soman, V. and Felig, P. (1977) J. Clin. Invest. 60, 
224-232. 
Slein, M.W. (1963) in: Methods of Enzymatic 
Analysis (Bergmeyer, H.U. ed) pp.117-123, 
Academic Press, London, New York. 
Rodbell, M. (1964) J. Biol. Chem. 239, 375-380. 
Krebs, H.A. and Henseleit, H. (1932) Hoppe- 
Seyler’s Z. Physiol. Chem. 210, 33-66. 
Garland, P.B. and Randle, P.J. (1962) Nature 196, 
987-988. 
Burton, K. (1956) Biochem. J. 62, 315-323. 
Hales, C.N., Luzio, J.P. and Siddle, K. (1978) 
Biochem. Sot. Symp. 43, 97-135. 
Londos, C., Cooper, D.M.F. and Wolff, J. (1980) 
Proc. Natl. Acad. Sci. USA 77, 2551-2554. 
Trost, T. and Stock, K. (1977) Naunyn- 
Schmiedeberg’s Arch. Pharmacol. 299, 33-40. 
Londos, C., Cooper, D.M.F., Schlegel, W. and 
Rodbell, M. (1978) Proc. Natl. Acad. Sci. USA 75, 
5362-5366. 
Fain, J.N. and Malbon, C.C. (1979) Mol. Cell 
Biochem. 25, 143-169. 
Wolff, J., Londos, C. and Cooper, D.M.F. (1981) 
Adv. Cyclic Nucl. Res. 14, 199-214. 
Fernandez, B.M. and Saggerson, E.D. (1978) 
Biochem. J. 174, 111-118. 
Le Febvre, P. (1975) Biochem. Pharmacol. 24, 
1261-1266. 
Sacca, L., Perez, G., Certeni, G., Trimareo, B. and 
Rengo, F. (1976) Horm. Metab. Res. 9, 209-212. 
Zapf, J., Feuerlein, D., Waldvogel, M. and 
Froesch, E.R. (1975) Diabetologia 11, 509-516. 
Desbuquois, B. and Laudat, M.-H. (1974) Mol. 
Cell Endocrinol. 1, 355-370. 
Sonne, 0. and Gliemann, J. (1977) Biochim. Bio- 
phys. Acta 499, 259-272. 
138 
